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Induction of oxidative stress is a key component of cancer therapy. Pro-oxidant drugs have been demonstrated to
enhance the efficacy of radiotherapy and chemotherapy. An emerging concept is that therapeutic outcomes are dictated
by the differential redox buffering reserve in subpopulations of malignant cells, indicating the need for noninvasive
biomarkers of tumor redox that can be used for dose identification and response assessment in a longitudinal setting.
Magnetic resonance imaging (MRI) enhanced with the thiol-binding contrast agent Gd-LC6-SH, and hemodynamic
response imaging (HRI) in combination with hypercapnia and hyperoxia were investigated as biomarkers of the
pharmacodynamics of the small molecule pro-oxidant imexon (IMX). Human multiple myeloma cell lines 8226/S and an
IMX-resistant variant, 8226/IM10,were established as contralateral tumors in SCIDmice. T1slope, anMRImeasure of the
washout rate of Gd-LC6-SH, was significantly lower post-IMX therapy in 8226/S tumors compared with vehicle controls,
indicating treatment-relatedoxidizationof the tumormicroenvironment,whichwas confirmedby analysis of tumor tissue
for thiols. T1slope and ex vivo assays for thiols both indicated a more reduced microenvironment in 8226/IM10 tumors
following IMX therapy. HRI with hypercapnia challenge revealed IMX inhibition of vascular dilation in 8226/S tumors but
not 8226/IM10 tumors, consistent with decreased immunohistochemical staining for smooth muscle actin in treated
8226/S tumors. MRI enhanced with Gd-LC6-SH, and HRI coupled with a hypercapnic challenge provide noninvasive
biomarkers of tumor response to the redox modulator imexon.
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Oxygen free radicals, or reactive oxygen species (ROS), are
by-products of normal mitochondrial metabolism [1]. Historically,
ROS, such as superoxide anion (O2˙
−), hydrogen peroxide (H2O2),
and the hydroxyl radical (OH˙), have been recognized for their role in
age-related damage of proteins, lipids, and DNA. More recently,
studies have identified ROS as key second messengers that can
activate signaling pathways to drive essential physiological functions,
including cell division, migration, metabolic activity, and pro-
grammed cell death. The intracellular activity of ROS in signal
transduction and the overall redox status of the cell are tightly
regulated by endogenous antioxidant systems. An imbalance of the
redox system in tumor cells has been identified as a potential
therapeutic target for anticancer drugs [2,3].Imexon (IMX) is an aziridine-containing iminopyrrolidone that is
in phase II clinical trials for various malignancies [4–8]. Previous
studies have demonstrated that IMX reacts with sulfhydryl groups
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loss of mitochondrial membrane potential, and apoptosis [9–11].
Biochemical analyses have shown that this interaction occurs via
classical aziridine ring opening to bind glutathione (GSH) or via
nucleophilic attack at the cyclic amidine moiety by the sulfur atom in
cysteine [12].
Inactivation of common chemotherapeutic agents, such as
platinum drugs, nitrogen mustards, doxorubicin, and nitrosoureas,
can occur via conjugation of reduced glutathione with electrophilic
centers of these molecules. Through hydrogen donation,
sulfhydryl-containing species such as cysteine and GSH can also
effect repair of DNA damage produced by ionizing radiation [13].
Therapeutic agents such as IMX that deplete tumor thiol reserves may
therefore enhance the anticancer efficacies of both chemotherapy and
radiotherapy. In a recently concluded phase 2 study, patients with
relapsed/refractory B-cell non-Hodgkin lymphoma were treated with
IMX as a single agent. Progression-free survival was calculated, and
clinical response was correlated with a redox signature score that was
generated from gene expression analyses of both pretreatment tumor
biopsies and pre- and posttreatment peripheral blood mononuclear
cells [4]. These laboratory correlates demonstrated that patients with
higher redox scores were more likely to respond to the pro-oxidant
IMX. However, no reliable method currently exists for measuring
intratumoral oxidative stress directly and accurately that would allow
a priori prediction of patient response. There is a clinical need for a
noninvasive correlate of oxidative stress to inform treatment selection,
monitor tumor response longitudinally, and assess spatial heteroge-
neity in solid tumors. The objectives of this study were therefore to
develop imaging biomarkers of the pharmacodynamics of IMX and to
relate our findings to differences in the responses of drug-sensitive and
drug-resistant tumors to IMX.
Gd-LC6-SH is a thiol-bearing DOTA complex of gadolinium, and
we have previously demonstrated that the decrease in tumor
longitudinal relaxation time produced on magnetic resonance
imaging (MRI) by Gd-LC6-SH at 60 minutes postinjection (=
ΔT1) was correlated with tumor thiol content in Mia-PaCa-2
pancreatic and NCI-N87 gastric cancer xenografts [14]. A limitation
to the interpretation of tumor ΔT1 in terms of tumor redox status is
that it would also be a function of tumor perfusion that delivers the
agent and its extracellular volume of distribution within the tumor.
Gd-LC6-SH binds to plasma albumin at the conserved Cys34 site,
which prolongs its retention in the tumor microenvironment. The
washout rate of Gd-LC6-SH from the tumor will be a function of the
local concentration of small molecule thiols that compete for binding
to albumin at the same site. We hypothesize that the rate of change of
tumor T1 during washout of Gd-LC6-SH (= T1slope) is a biomarker
of tumor redox status that is independent of tumor perfusion and
extracellular distribution volume fraction; faster washout rates will be
expected in more reducing microenvironments.
In this study, we report that the T1slopes of IMX-sensitive 8226/S
and IMX-resistant 8226/IM10 multiple myeloma tumor xenografts
measured in vivo in control and IMX-treated mice correlate with
tumor thiol content measured ex vivo using histologic and enzymatic
assays. Treatment of 8226/IM10 tumors with the pro-oxidant IMX
produced a trend toward a more reduced tumor microenvironment,
suggesting a compensatory response in these IMX-resistant tumors.
We also report that hemodynamic response imaging (HRI) by MRI
in combination with hypercapnia provides a noninvasive biomarker
for the effect of IMX on tumor vascular maturation. We discuss thepotential for Gd-LC6-SH MRI and HRI in pretherapy prognosti-
cation and posttherapy response assessment.
Materials and Methods
Mice, Tumors, and Drug
All animal experiments were conducted in accordance with the
guidelines of the Institutional Animal Care and Use Committee at the
University of Arizona. The 8226/S human myeloma cells were
originally obtained from ATCC, and the IMX-resistant 8226/IM10
cell line was created by continuous exposure to IMX as previously
described [15,16]. Dual xenografts on contralateral flanks of
6-week-old female SCID mice were established by subcutaneous
injection of 10 × 106 cells. Animals were monitored every 3 days for
general health, body weight, and tumor volume by caliper measure.
Mean tumor volume was used to stratify animals into equal treatment
groups when the tumors were approximately 100 to 250 mm3. IMX
was generously provided by AmpliMed Corp, Tucson, AZ, and was
prepared as a 15-mg/ml solution in 0.9% NaCl. Animals were
administered either IMX (150 mg/kg, intraperitoneally [i.p.]) or saline
(0.25ml per 25 g, i.p.) on a day 1-5-9 schedule.MRI was done on day 0
(pretreatment) and 2 hours post drug administration on day 9.
Hemodynamic Response Imaging
All MRI measurements were made on a Bruker Biospec MR
imager with a 7-T horizontal bore magnet equipped with 600-mT/m
self-shielded gradients (Bruker Biospin, Billerica, MA). Mice were
anesthetized using isoflurane (1-2%, rest air) and cannulated at the
tail vein for injections. T2*-weighted gradient echo (GRE) images
were collected using the following parameters: repetition time (TR) =
200 milliseconds, echo time (TE) = 15 milliseconds, flip angle (FA) =
45°, matrix = 128 × 128, number of averages (NA) = 8. Six
consecutive images were acquired with the mouse breathing air
followed by 7 consecutive images after the breathing gas was changed
to air-CO2 (95% air, 5% CO2) and a final 7 consecutive images
acquired as the animal breathed carbogen (95% O2, 5% CO2). The
first image acquired following each change in breathing mix was left
out during data analysis to account for gas exchange and physiological
equilibration. Indices of vasodilation (VD) and vascular function
(VF) were calculated by the method of Abramovitch and colleagues
[17,18], as follows:
VF ¼ ln IO2‐CO2
I air‐CO2
 
= TE•CMRIð Þ ð1Þ
VD ¼ ln I air‐CO2
I air
 
= TE•CMRIð Þ ð2Þ
Here Iair, Iair-CO2, and IO2-CO2 are the T2*-weighted MRI signal
intensities with the mouse breathing the respective gas mixes. The
constant CMRI incorporates the effects of the magnetic field strength
and the susceptibility of deoxyhemoglobin and was scaled linearly
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prepared as a 25-mM solution in injectable saline at pH 7.4 for
intravenous (i.v.) administration. After acquisition of scout MR
images, a precontrast T1 map and proton-density map were acquired.
This was followed by a co-registered dynamic GRE series (TR = 78
milliseconds, TE = 3.5 milliseconds, FA = 75°, NA = 1, number of
repetitions = 60, scan time = 20 minutes) during which the contrast
medium was administered. After the start of the dynamic series,
Gd-LC6-SH (0.05 mmol/kg) was administered via the tail vein
cannula over 1 minute and chased with 0.15 ml of saline injected
over 1 minute. After the dynamic series, 10 co-registered GRE images
(TR = 78 milliseconds, TE = 3.5 milliseconds, FA = 75°, NA = 12)
were acquired at regular intervals to 60 minutes after injection of
Gd-LC6-SH. Together with the precontrast proton density map,
these 10 postcontrast T1-weighted images were used to compute 10
postcontrast T1 maps. In oxidizing microenvironments, Gd-LC6-SH
would remain bound to albumin and only be cleared slowly because
of the “enhanced permeability and retention” effect. In reducing
microenvironments, competitive binding by other small molecule
thiols would release the Gd-LC6-SH from the albumin and accelerate
its washout. The parameter ΔT1 was calculated as the difference in
tumor T1 precontrast versus 60 minutes postinjection of
Gd-LC6-SH (Figure 1). A larger ΔT1 would be expected in oxidizing
tumor microenvironments than in reducing microenvironments. This
effect on tumor ΔT1 is enhanced by the 47% higher longitudinal
relaxivity (r1) of Gd-LC6-SH when it is bound to albumin compared
with the r1 of the unbound molecule [21,22]. In addition to interstitial
albumin, exofacial protein thiols could constitute another static pool of
thiol-binding sites in the tumor [23,24]. The dimensionless parameter
T1slope was calculated as the rate of change of tumor T1 between ~20
and 60 minutes postinjection of Gd-LC6-SH from tumor pixels that
exhibited a minimum of 20% peak signal enhancement postinjection of
Gd-LC6-SH (Figure 1). A larger T1slope would be expected in reducing
tumor microenvironments than in oxidizing microenvironments.
Tissue Assay for Thiols
Tumors from mice in the Gd-LC6-SH MRI experiment were
rapidly harvested following sacrifice by cervical dislocation under
anesthesia (4% isoflurane in O2). This was done the day after imaging
to allow for complete clearance of Gd-LC6-SH from the animals.
Mice were administered a fourth dose of IMX (150 mg/kg, i.p.) or
saline (0.25 ml per 25 g, i.p.) 2 hours before sacrifice. Excised tumors
were immediately placed into cryovials and frozen. Frozen tumorFigure 1. Example of (A) transaxial T2-weighted MR image of a mouse
precontrast T1 map and (C) post-GdLC6SH T1 map. Also prominently
T1slope from the temporal variation of tumor T1 following i.v. injectisections were stained with mercury orange and analyzed as described
previously [14]. Thiol content in tumor tissue extracts was assayed
using the Fluoro Thiol kit (Cell Technology Inc., Mountain View,
CA). Briefly, 18 to 40 mg of tumor tissue was homogenized on ice in
the supplied lysis buffer. Tumor lysates were centrifuged, and the
clarified supernatant was immediately analyzed on a fluorescence
plate reader with excitation at 485 nm and emission at 595 nm.
Fluorescence readings were calibrated against the supplied GSH
standard and normalized to sample protein content. Protein
concentration in the tumor lysates was determined separately by
following the standard protocol for the Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, lL).
Immunohistochemistry (IHC)
After completion of imaging on day 9, mice in the HRI experiment
were kept anesthetized with isoflurane while the breathing gas was
switched to air. Mice were then administered 2-nitroimidazole
(pimonidazole, 60 mg/kg) via the tail vein line. After 30 minutes, the
animals were sacrificed, and the tumors were harvested, fixed in
formalin, and embedded in paraffin for further processing. Tissue
sections were stained with hematoxylin and eosin, or assayed by IHC
for detection of pimonidazole adducts (Hypoxyprobe EF5 antibody),
or CD31 (Abcam ab28364), or smooth muscle actin (SMA, Abcam
ab32575). Pimonidazole analysis was done by collecting
color-balanced images of five independent fields (20× magnification)
of each tumor. A representative cell demonstrating “minimal positive
intensity” was selected, and the images were converted to gray scale
using ImageJ (National Institutes of Health). Gray-scale histograms
were used to determine the total pixel count over threshold in each
image, and the mean positive area was calculated on each tumor.
CD31- and SMA-stained slides were scanned with the Aperio
ScanScope XT (Vista, CA), and positive pixel analysis was performed
using Aperio Genie v1 software. Briefly, the algorithm measured
staining intensity across the entire area of the tumor and classified the
number of pixels containing stained tissue. The results are presented
as percent positivity, which was calculated as the number of positive
pixels divided by the total number of pixels multiplied by 100.
Results
Gd-LC6-SH MRI in Pro-Oxidant Chemotherapy
Tumor ΔT1 was measured before the start of treatment (day 0) and
again 2 hours following a third dose of saline or IMX (day 9). In thewith arrows pointing to the dual tumors, and the corresponding (B)
visible is the bladder. (D) The calculation of the parameters T1 and
on of Gd-LC6-SH at time zero.
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treatment schedule relative to pretreatment ΔT1, although this
decrease did not achieve statistical significance (Figure 2A, P = .062).
Treatment of 8226/S tumors with IMX resulted in a significant
increase in ΔT1 at the end of the day 1-5-9 treatment schedule
relative to saline treatment (Figure 2A, P = .007) and a nonsignificant
increase relative to pretreatment ΔT1 (Figure 2A, P = .096). 8226/
IM10 tumors did not show an appreciable change in ΔT1 over the
9-day saline treatment schedule but exhibited a nonsignificant
decrease in ΔT1 at the end of the IMX treatment schedule relative to
saline treatment (Figure 2A, P = .453). Posttreatment versus
pretreatment changes in tumor ΔT1, calculated for each animal, are
summarized in Figure 2B.
We have also examined the parameter T1slope, which is a
dimensionless measure of the washout rate of Gd-LC6-SH. T1slope
did not change appreciably in either tumor type following treatment
with saline. T1slope was significantly decreased in 8226/S tumors
following treatment with IMX, relative to saline controls, indicating a
shift toward a more oxidizing tumor microenvironment (Figure 3A).
Consistent with this MRI finding, the thiol content of 8226/S tumors
was observed to be significantly decreased by IMX treatment relative
to saline controls, as measured by mercury orange staining
(Figure 3B) and the Fluoro Thiol assay (Figure 3C). The T1slope
of 8226/IM10 tumors was higher following treatment with IMX
relative to saline controls, indicating a movement of tumor redox in
the reducing direction (Figure 3A). Mercury orange staining and the
Fluoro Thiol assay confirmed that treatment with IMX paradoxically
increased thiol content in 8226/IM10 tumors (Figure 3, B and C).
Although the difference in the response of 8226/IM10 tumors to
saline versus IMX did not achieve statistical significance, these slight
increases were consistent across all three measures: T1slope, mercury
orange, and Fluoro Thiol. By all three measures, the difference in the
response of the two tumor types to IMX was statistically significant
(Figure 3, A–C).
Hemodynamic Response Imaging
We have computed a tumor VD from the change in T2*-weighted
MRI signal intensity produced upon switching the inhaled gas fromFigure 2. (A) T1 following administration of Gd-LC6-SH, measured pre
(mean ± SEM, #P = .007). (B) Posttherapy versus pretherapy change
and 8226/IM10 tumors (mean ± SEM, n = 8, *P = .016).air to air-CO2. We have also calculated the change in T2*-weighted
MRI signal intensity produced by a further switch of the inhaled gas
from air-CO2 to oxygen-CO2 and used it to compute an index of VF.
An increase in VD was calculated in 8226/S tumors over the day 1-5-9
treatment with saline, indicating progressive vascular maturation during
tumor growth in this period (Figure 4A). Treatment of 8226/S tumors
with IMX produced a significant decrease in VD relative to the saline
controls over this same period (Figure 4A, P = .030), indicating that
IMX interferes with vascular maturation in these tumors. Tumor VD
was observed to decrease in 8226/IM10 tumors over 9 days of treatment
with both saline and IMX, with no significant difference between the
two treatment groups in these IMX-resistant tumors (Figure 4B). No
significant differences were found in VF between saline and IMX
treatment in either 8226/S or 8226/IM10 tumors (Figure 4).
Immunohistochemistry
Mice in the HRI experiment were infused with the
2-nitroimidazole compound pimonidazole. In a complex series of
bioreductive reactions catalyzed by cellular nitroreductase enzymes
under conditions of hypoxia, pimonidazole forms adducts with
thiol-rich macromolecules [25]. We have detected the pimonidazole-
protein conjugate in formalin-fixed paraffin-embedded (FFPE) tissue
sections by IHC. Mean pimonidazole staining in 8226/S and 8226/
IM10 xenograft tumors from individual SCIDmice treated with IMX
or vehicle control is shown in Figure 5A, and a representative image
demonstrating the pixel density defined as “positive” is shown in
Figure 5B. IMX treatment increases pimonidazole staining in
IMX-sensitive (8226/S) tumors by 2.6-fold and in IMX-resistant
(8226/IM10) xenografts by 9.1-fold. We assessed the tumor
microvessel density with the panendothelial marker CD31 and
relative pericyte coverage by the SMA/CD31 ratio in FFPE sections
from the xenograft tumors. The SMA/CD31 ratio indicated that a
significantly greater proportion of the vasculature in the IMX-treated
8226/IM10 tumors is associated with pericytes, indicative of vascular
maturity or normalization, relative to saline-treated control 8226/
IM10 tumors (Figure 6A). Figure 6B demonstrates CD31 and
SMA staining in serial sections from a representative 8226/S
xenograft tumor.therapy, postsaline, and post-IMX, in 8226/S and 8226/IM10 tumors
of T1 following administration of Gd-LC6-SH in individual 8226/S
Figure 3. (A) Posttherapy versus pretherapy change of T1slope in individual 8226/S and 8226/IM10 tumors (mean ± SEM, n = 8, *P =
.044, #P = .018). (B) Mercury Orange staining for thiols in frozen sections of 8226/S and 8226/IM10 tumors following saline or IMX
treatment (mean ± SEM, n= 5, *P= .003, #P= .004). (C) Fluoro Thiol assay for thiols, normalized to protein content, in extracts of 8226/S
and 8226/IM10 tumors from mice treated with saline or IMX (mean ± SEM, n = 3, *P = .026, #P = .036).
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Gd-LC6-SH is an MRI contrast agent that spontaneously binds to
the conserved Cys34 residue in plasma albumin following i.v.
administration. Once bound to protein, Gd-LC6-SH will be subject
to the “enhanced permeability and retention” effect in tumors,
whereas the unbound small molecule will be cleared relatively rapidly.
The rate of washout of gadolinium from tumor will be a function of
the local concentration of competing thiols that can dislodge
Gd-LC6-SH from macromolecular binding sites. We have developed
T1slope, the rate of change of tumor T1 during washout of
Gd-LC6-SH, as a biomarker of local extracellular tissue redox status
that is independent of tumor perfusion and contrast agent volume of
distribution in the tumors. For example, in IMX-sensitive 8226/S
tumors, the ΔT1 was measured to decrease over the 9-day treatment
with saline (Figure 2B), whereas T1slope remained essentially
unchanged over the same period (Figure 3A). This difference is
consistent with a decrease in perfusion delivery and/or extracellular
volume of distribution of Gd-LC6-SH in 8226/S tumors due to
growth rather than any change in tumor extracellular redox arising
from saline “treatment.” The decrease in 8226/S tumor T1slope overFigure 4. HRI evaluation of VD (using hypercapnia, dimensionless) an
IMX-resistant 8226/IM10 tumors grown as contralateral xenografts in
significant decrease in VD was observed following IMX treatment rethe 9-day treatment with IMX (Figure 3A) points to a more oxidizing
tumor microenvironment following treatment, consistent with the
known pro-oxidant and thiol-reactive chemical properties of IMX.
This was corroborated by ex vivo assays of 8226/S tumor thiol
content (Figure 3, B and C). The posttherapy T1slope of
IMX-resistant 8226/IM10 tumors was higher following the 9-day
IMX treatment period but unchanged over the 9-day saline control
regimen, although this difference was not statistically significant
(Figure 3A). This trend indicates a more reducing microenvironment
in 8226/IM10 tumors in response to IMX treatment and was
mirrored in ex vivo assays of 8226/IM10 tumor thiol content
(Figure 3, B and C). IHC of pimonidazole staining, an indirect
indicator of the availability of intracellular macromolecular and
nonprotein thiols, was significantly higher in FFPE sections of
IMX-treated 8226/IM10 tumors than in saline-treated controls
(Figure 5). These observations correlate well with our previous work
demonstrating that the IMX-resistant 8226/IM10 cells have higher
basal expression of antioxidant systems [15], higher levels of the
intracellular antioxidant glutathione, and increased expression of
glutathione peroxidase [16] relative to the parent 8226/S cell line.d VF (using hyperoxia, dimensionless) in IMX-sensitive 8226/S and
SCID mice treated with either saline or IMX (mean ± SEM, n= 5). A
lative to saline controls in only the 8226/S tumors (*P = .030).
Figure 5. Immunohistochemistry of pimonidazole staining in IMX-sensitive 8226/S and IMX-resistant 8226/IM10 tumors grown in SCID
mice treated with either saline (CT, control) or IMX. (A) Mean pixel density above threshold of pimonidazole staining in FFPE tissue (n= 5
images per slide). (B) Representative image of 8226/S tumor following EF5 staining. (i) 10× image. (ii) Inset demonstrating “minimum
positive cell” used to determine threshold for quantitative analysis. (iii) Gray-scale conversion of (ii).
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response in resistant cells that is triggered by IMX challenge. An
imaging method to monitor the degree and spatial extent of such a
compensatory response within a tumor subpopulation will enable the
oncologist to adapt therapy and circumvent the onset of resistance.
The plasma half-life of IMX in mice is 12 to 15 minutes after
intraperitoneal injection [26], and in these experiments, we injected
Gd-LC6-SH into the mice 2 hours after the IMX to minimize direct
reaction between the two species. Another concern is whether IMX
treatment decreases the availability of albumin-Cys34 and what effect
this might have on the utility of tumor ΔT1 and T1slope as measures
of tumor redox. Albumin-Cys34 exists in two major forms in plasma,
as the thiolate anion albumin-Cys34-S− and as a mixed disulfide
albumin-Cys34-S-S-X where X might be a small molecule thiol such
as cysteine or homocysteine. The careful work of Jacobsen and
colleagues on the binding of homocysteine to albumin [27] suggests
that Gd-LC6-SH would react primarily with albumin-Cys34-S-S-X in
a redox-neutral exchange rather than participate in oxidative disulfide
bond formation with albumin-Cys34-S− that is likely to be slow
relative to the in vivo clearance times of unbound Gd-LC6-SH.
Although IMX may be expected to have some reactivity toward
albumin-Cys34-S−, it does not react readily with disulfides [12] and
would therefore not be expected to decrease availability of
albumin-Cys34-S-S-X as a target for binding of Gd-LC6-SH. A
practical concern when measuring T1slope is the need to image for a
long period (60 minutes) following injection of the contrast agent;this is necessitated by the time required for a significant change in
tumor T1 to manifest following gadolinium washout. For a given
change in tumor gadolinium concentration, a proportional change in
tumor relaxation rate (R1 = 1/T1) is produced, with the
proportionality constant being the r1 relaxivity of the gadolinium.
Our ongoing work is focused on developing variants of Gd-LC6-SH
with higher r1 relaxivities when bound to albumin, which will result
in larger T1slope values for a given washout rate of tissue gadolinium,
thereby decreasing the imaging time required.
Abramovitch and coworkers developed HRI driven by hypercapnia
(elevated CO2) and hyperoxia (elevated O2) for in vivo assessment of
vascular maturation and vascular function, respectively, in tumors and
normal parenchyma [17,18]. They have argued that the change in
MRI signal intensity due to hypercapnia (captured in VD) arises from
a change in the apparent longitudinal relaxation time T1 due to local
blood flow changes stemming from vasodilation. In contrast to
mature capillaries, immature blood vessels lacking pericytes and
smooth muscle cells do not dilate in response to hypercapnia, and VD
has the potential to be a noninvasive reporter of vascular maturation.
They have also argued that a change in MRI signal intensity due to
hyperoxia (captured in VF) would stem from a change in T2*
produced by changes in local deoxyhemoglobin concentration.
Subject to the caveat that oxygen saturation of hemoglobin at the
lungs may already be near maximal under air breathing, VF may
noninvasively report on vascular function. HRI revealed that 8226/S
tumors in IMX-treated mice exhibit significantly lower vasodilation
Figure 6. Immunohistochemistry of SMA and CD31 staining in IMX-sensitive 8226/S and IMX-resistant 8226/IM10 tumors grown in SCID
mice treated with either saline (CT, control) or IMX. (A) Positive pixel analysis was used to determine the percent positivity across the
whole area of each xenograft tumor. Data are presented as the ratio of the mean percent positivity of SMA to the mean percent positivity
of CD31, ± SEM. *P b .05. (B). Representative serial sections from an 8226/S xenograft tumor stained for (i) CD31 and (ii) SMA.
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differences were observed on HRI in the IMX-resistant 8226/IM10
tumors, although the ratio of SMA to CD31 staining was significantly
higher in IMX-treated tumors than in saline-treated controls. This
finding once again supports the contention that IMX-resistant tumors
with enhanced antioxidation response system may undergo a
“rebound” effect following challenge with redox-active agents. We
propose that HRI perturbed with hypercapnia (air versus air-CO2) is
a clinically translatable and noninvasive marker for assessment of
tumor sensitivity to IMX.
Therapies that deplete the tumor antioxidant pool can enhance
chemosensitivity and radiation response. Resistance to co-therapy
with redox modulators can arise from a compensatory antioxidant
response by a subpopulation of tumor cells. Rational identification of
the proper dose and dosing schedule for a redox modulator will
require the ability to longitudinally monitor tumor redox status as
well as its heterogeneity within solid tumors. In this study, we have
used in vivoMRI to measure T1slope, the rate of change of tumor T1
during washout of Gd-LC6-SH. The T1slope of IMX-sensitive
8226/S and IMX-resistant 8226/IM10 multiple myeloma tumor
xenografts in control and IMX-treated mice is predictive of tumor
thiol content change with therapy, confirmed by ex vivo histologic
and enzymatic assays for thiols. We envision clinical application for
pretreatment identification of patients who are more likely to respondto redox modulators such as IMX, as well as for longitudinal
assessment to enable adaptive, personalized, treatment with
redox-sensitive chemotherapies and radiation with or without
co-treatment with a redox modulator. In the near term, HRI in
conjunction with hypercapnia provides a readily translatable and
noninvasive biomarker for the longitudinal monitoring of tumor
response to IMX in clinical studies. Our continuing efforts are
directed at combining imaging biomarkers with pretreatment
biomarkers such as the redox signature score [4] to increase the
overall predictive power and guide clinical therapy.
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